|
Aug 8
|
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
|
|
Aug 7
|
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2
|
|
Aug 7
|
CytomX Therapeutics: Q2 Earnings Snapshot
|
|
Aug 7
|
CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
|
|
Aug 3
|
CytomX Therapeutics (NASDAQ:CTMX) shareholders have earned a 79% return over the last year
|
|
Jul 31
|
CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025
|
|
Jul 25
|
CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate
|
|
Jan 8
|
CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Jan 7
|
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
|
|
Jan 6
|
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
|
|
Jan 3
|
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year
|
|
Jan 3
|
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
|
|
Jan 3
|
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
|
|
Jan 3
|
Neumora Stock Hits Record Low on Depression Drug Study Failure
|
|
Jan 2
|
PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
|
|
Jan 2
|
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
|